Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8718-8728

  Bhat, Rohit ^a   Tummalapalli, Sreedhar R ^a   Rotella, David P ^a  

^a MONTCLAIR STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[2 CARBAMOYL 5 (4,5,6,7 TETRAHYDRO 6,6 DIMETHYL 4 OXO 3 (TRIFLUOROMETHYL) 1H INDAZOL 1 YL)PHENYL]AMINO]CYCLOHEXYL GLYCINATE; ABIRATERONE; AMIDE; ANAPLASTIC LYMPHOMA KINASE; BORTEZOMIB; DABRAFENIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; GANETESPIB; GELDANAMYCIN; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; LACTONE DERIVATIVE; LUMINESPIB; NOVOBIOCIN; ONALESPIB; RADICICOL; RHODOPSIN; SMALL INTERFERING RNA; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; ISOPROTEIN; MACROCYCLIC LACTAM; NEUROPROTECTIVE AGENT; TAU PROTEIN;

ALLOSTERISM; ANTIPROLIFERATIVE ACTIVITY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOTOXICITY; ENDOPLASMIC RETICULUM; GASTROINTESTINAL STROMAL TUMOR; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; ISOTOPE LABELING; LUNG ADENOCARCINOMA; NEUROPROTECTION; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; TELOMERE HOMEOSTASIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; METABOLISM; NEOPLASMS; PHYSIOLOGY; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; NEUROPROTECTIVE AGENTS; PROTEIN ISOFORMS; RATS; TAU PROTEINS;

EID: 84921687193     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500823a     Document Type: Review

References (69)

1. Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W.-C. Heat shock protein 90: inhibitors in clinical trials J. Med. Chem. 2010, 53, 3-17
2. Roughley, S. D.; Hubbard, R. E. How well can fragments explore accessed chemical space? A case study from heat shock protein 90 J. Med. Chem. 2011, 54, 3989-4005
3. Massey, A. J. ATPases as drug targets: insights from heat shock proteins 70 and 90 J. Med. Chem. 2010, 53, 7280-7286
4. Huryn, D. M.; Resnick, L. O.; Wipf, P. Contributions of academic laboratories to the discovery and development of chemical biology tools J. Med. Chem. 2013, 56, 7161-7176
5. Clare, D. K.; Saibil, H. R. ATP-driven molecular chaperone machines Biopolymers 2013, 99, 846-859
6. Paul, S.; Mahanta, S. Association of heat shock proteins in various neurodegenerative disorders: Is it a master key to open the therapeutic door? Mol. Cell. Biochem. 2014, 386, 45-61
7. Hong, D. S.; Banerji, U.; Tavana, B.; George, G. C.; Aaron, J.; Kurzrock, R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions Cancer Treat. Rev. 2013, 39, 375-387
8. Vasko, R. C.; Rodriguez, R. A.; Cunningham, C. N.; Ardi, V. C.; Agard, D. A.; McAlpine, S. R. Mechanistic studies of sansalvamide A-amide: an allosteric modulator of Hsp90 ACS Med. Chem. Lett. 2010, 1, 4-8
9. Sreedhar, A. S.; Kalmar, E.; Csermely, P.; Shen, Y. F. Hsp90 isoforms: functions, expression and clinical importance FEBS Lett. 2004, 562, 11-15
10. Okayama, S.; Kopelvich, L.; Balmus, G.; Weiss, R. S.; Herbert, B.-S.; Dannenberg, A. J.; Subbaramaiah, K. p53 protein regulates Hsp90 ATPase activity and thereby Wnt signaling by modulating Aha1 expression J. Biol. Chem. 2014, 289, 6513-6525
11. Fierro-Monti, I.; Echeverria, P.; Racle, J.; Hernandez, C.; Picard, D.; Quadroni, M. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy PLoS One 2013, 8, e80425
12. Batulan, Z.; Taylor, D. M.; Aarons, R. J.; Minotti, S.; Doroudchi, M. M.; Nalbantoglu, J.; Durham, H. D. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis Neurobiol. Dis. 2006, 24, 213-225
13. Chen, Y.; Wang, B.; Liu, D.; Li, J. J.; Xue, Y.; Sakata, K.; Zhu, L.-Q.; Heldt, S. A.; Xu, H.; Liao, F.-F. Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment J. Neurosci. 2014, 34, 2464-2470
14. Ho, S. W.; Tsui, Y. T. C.; Wong, T. T.; Cheung, S. K.-K.; Goggins, W. B.; Yi, L. M.; Cheng, K. K.; Baum, L. Effects of 17-allylamino-17-demthoxygeldanamycin (17-AAG) in transgenic mouse models of frontotemporal lobar degeneration and Alzheimers disease Transl. Neurodegener. 2014, 2, 24
15. Cha, J. R. C.; St. Louis, K. J. H.; Tradewell, M. L.; Gentil, B. J.; Minotti, S.; Jaffer, Z. M.; Chen, R.; Rubenstein, A. E.; Durham, H. D. A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo Cell Stress Chaperones 2014, 19, 421-435
16. Karagöz, G. E.; Duarte, A. M. S.; Akoury, E.; Ippel, H.; Biernat, J.; Luengo, T. M.; Radli, M.; Didenko, T.; Nordhues, B. A.; Veprintsev, D. B.; Dickey, C. A.; Mandelkow, E.; Zweckstetter, M.; Boelens, R.; Madi, T.; Rüdiger, S. G. D. Hsp90-tau complex reveals molecular basis for specificity in chaperone action Cell 2014, 156, 963-974
17. Alani, B.; Salehi, R.; Sadeghi, P.; Zare, M.; Khodagholi, F.; Arefian, E.; Hakemi, M. G.; Digaleh, H. Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells J. Mol. Neurosci. 2014, 52, 392-402
18. Mendes, H. F.; Cheetham, M. E. Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa Hum. Mol. Genet. 2008, 17, 3043-3054
19. Machajewski, T. D.; Menezes, D.; Gao, Z. Discovery and Selection of NVP-HSP990 as a Clinical Candidate. In Inhibitors of Molecular Chaperones as Therapeutic Agents; Machajewski, T. D.; Gao, Z., Eds.; Royal Society of Chemistry: Cambridge, U.K., 2014; pp 241-258.
20. Aguila, M.; Bevilaqua, D.; McCulley, C.; Schwarz, N.; Athanasiou, D.; Kanuga, N.; Novoselov, S. S.; Lange, C. A. K.; Ali, R. R.; Bainbridge, J. W.; Gias, C.; Coffey, P. J.; Garriga, P.; Cheetham, M. E. Hsp90 inhibition protects against inherited retinal degeneration Hum. Mol. Genet. 2014, 23, 2164-2175
21. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim. Biophys. Acta 2012, 1823, 742-755
22. Oki, Y.; Copeland, A.; Romaguera, J.; Fayad, L.; Fanale, M.; de Castro Faria, S.; Medeiros, L. J.; Ivy, P.; Younes, A. Clinical experience with the heat shock protein-90 inhibitor tanespimycin in patients with relapsed lymphoma Leuk. Lymphoma 2012, 53, 990-992
23. Pacey, S.; Gore, M.; Chao, D.; Banerji, U.; Larkin, J.; Sarker, S.; Owen, K.; Asad, Y.; Raynaud, F.; Walton, M.; Judson, I.; Workman, P.; Eisen, T. A phase II trial of 17-allylamino, 17-demthoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma Invest. New Drugs 2012, 30, 341-349
24. Richardson, P. G.; Badros, A. Z.; Jaganath, S.; Tarantolo, S.; Wolf, J. L.; Albitar, M.; Berman, D.; Messina, M.; Anderson, K. C. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma Br. J. Haematol. 2010, 150, 428-437
25. Sharp, S. Y.; Boxall, K.; Rowlands, M.; Prodromou, C.; Roe, S. M.; Maloney, A. In vitro biological characterization of a novel synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitor Cancer Res. 2007, 67, 2206-2216
26. Felip, E.; Carcereny, E.; Barlesi, F.; Gandhi, L.; Sequist, L. V.; Kim, S.-W.; Groen, H. J. M.; Besse, B.; Kim, D.-W.; Smit, E.; Akimov, M.; Avsar, E.; Bailey, S.; Ofosu-Appiah, W.; Garon, E. B. Phase II activity of the Hsp90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer Ann. Oncol. 2012, 23 (Suppl. 9) 152-174
27. Woodhead, A. J.; Angove, H.; Carr, M. G.; Chessari, G.; Congreve, M.; Coyle, J. E. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design J. Med. Chem. 2010, 53, 5956-5969
28. Lin, T. Y.; Bear, M.; Du, Z.; Foley, K. P.; Ying, W.; Barsoum, J.; London, C. The novel Hsp90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors Exp. Hematol. 2008, 36, 1266-1277
29. Socinski, M. A.; Goldman, J.; El-Hariry, I.; Koczywas, M.; Vukovic, V.; Horn, L.; Paschold, E.; Salgia, R.; West, H.; Sequist, L. V.; Bonomi, P.; Brahmer, J.; Chen, L.-C.; Sandler, A.; Belani, C. P.; Webb, T.; Harper, H.; Huberman, M.; Ramalingam, S.; Wong, K.-K.; Teofilovici, F.; Guo, W.; Shapiro, G. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer Clin. Cancer Res. 2013, 19, 3068-3077
30. Pillai, R. N.; Ramalingam, S. S. Heat shock protein 90 inhibitors in non-small cell lung cancer Curr. Opin. Oncol. 2014, 26, 159-164
31. Kakashima, T.; Ishii, T.; Tagaya, H.; Seike, T.; Nakagawa, H.; Kanda, Y.; Akinaga, S.; Soga, S.; Shiotsu, Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonasnamycin heat shock protein 90 inhibitor in multiple myeloma cells Clin. Cancer Res. 2010, 16, 2792-2802
32. Hong, D. S.; Said, R.; Falchook, G. S.; Naing, A.; Moulder, S. L.; Tsimberidou, A. M.; Galluppi, G.; Dakappagari, N.; Storgard, C.; Kurzrock, R.; Rosen, L. S. Phase I study of BIIB028, a selective heat shock protein inhibitor in patients with refractory metastatic or locally advanced solid tumors Clin. Cancer Res. 2013, 19, 4824-4831
33. Stenderup, K.; Rosada, C.; Gavillet, B.; Vuagniaux, G.; Dam, T. N. Debio 0932, a new oral Hsp90 inhibitor alleviates psoriasis in a xenograft transplantation model Acta Derm.-Venereol. 2014, 10.2340/00015555-1838
34. Haystead, T.; Hughes, P. Discovery of the Serenex Hsp90 Inhibitor, SNX5422. In Inhibitors of Molecular Chaperones as Therapeutic Agents; Machajewski, T. D.; Gao, Z., Eds.; Royal Society of Chemistry: Cambridge, U.K., 2014; pp 198-212.
35. Reddy, N.; Voorhees, P. M.; Houk, B. E.; Brega, N.; Hinson, J. M., Jr.; Hillela, A. Phase I trial of the Hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies Clin. Lymphoma, Myeloma Leuk. 2013, 13, 385-391
36. Caldas-Lopes, E.; Cerchietti, L.; Ahn, J. H.; Clement, C. C.; Robles, A.; Rodina, A.; Moulick, K.; Taldone, T.; Gozman, A.; Guo, Y.; Wu, N.; deStanchina, E.; White, J.; Gross, S. S.; Ma, Y.; Varticovski, L.; Melnick, A.; Chiosis, G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple negative breast cancer models Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 8368-8373
37. Bussenius, J.; Blazey, C. M.; Aay, N.; Anand, N. K.; Arcalas, A.; Baik, T.; Bowles, O. J.; Buhr, C. A.; Costanzo, S.; Curtis, J. K.; DeFina, S. C.; Dubenko, L.; Heuer, T. S.; Huang, P.; Jaeger, C.; Joshi, A.; Kennedy, A. R.; Kim, A. I.; Lara, K.; Lee, J.; Li, J.; Lougheed, J. C.; Ma, S.; Malek, S.; Manalo, J. C.; Martini, J. F.; McGrath, G.; Nicoll, M.; Nuss, J. M.; Pack, M.; Peto, C. J.; Tsang, T. H.; Wang, L.; Womble, S. W.; Yakes, M.; Zhang, W.; Rice, K. D. Discovery of XL888: a novel tropane-derived small molecule inhibitor of Hsp90 Bioorg. Med. Chem. Lett. 2012, 22, 5396-5404
38. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein Hsp90-pp60vsrc heteroprotein complex formation by benzoquinone ansamycins: essential role for stress protein in oncogenic transformation Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8324-8328
39. Guo, W.; Reigan, P.; Siegel, D.; Ross, D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action Drug Metab. Dispos. 2008, 36, 2050-2057
40. Kitson, R. R. A.; Chang, C. H.; Xiong, R.; Williams, H. E. L.; Davis, A. L.; Lewis, W.; Dehn, D. L.; Siegel, D.; Roe, S. M.; Prodromou, C.; Ross, D.; Moody, C. J. Synthesis of 19-substituted geldanamycin with altered conformations and their binding to the heat shock protein Hsp90 Nat. Chem. 2013, 5, 307-314
41. Roe, S. M.; Prodromou, C.; OBrien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin J. Med. Chem. 1999, 42, 260-266
42. Day, J. E. H.; Sharp, S. Y.; Rowlands, M. G.; Aherne, W.; Hayes, A.; Raynaud, F. I.; Lewis, W.; Roe, S. M.; Prodromou, C.; Pearl, L. H.; Workman, P.; Moody, C. J. Targeting the Hsp90 molecular chaperone with novel macrolactams. Synthesis, structural, binding, and cellular studies ACS Chem. Biol. 2011, 6, 1339-1347
43. Brasca, M. G.; Mantegani, S.; Amboldi, N.; Bindi, S.; Caronni, D.; Casale, E.; Ceccarelli, W.; Colombo, N.; De Ponti, A.; Donati, D.; Ermoli, A.; Fachin, G.; Felder, E. R.; Ferguson, R. D.; Fiorelli, C.; Guanci, M.; Isacchi, A.; Pesenti, E.; Polucci, P.; Riceputi, L.; Sola, F.; Visco, C.; Zuccotto, F.; Fogliatto, G. Discovery of NMS-E937 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90) Bioorg. Med. Chem. 2013, 21, 7047-7063
44. Taddei, M.; Ferrini, S.; Giannotti, L.; Corsi, M.; Manetti, F.; Giannini, G.; Loredana, V.; Milazzo, F. M.; Alloatti, D.; Guglielmi, M. B.; Castorina, M.; Cervoni, M. L.; Barbarino, M.; Fodera, R.; Carollo, V.; Pisano, C.; Armaroli, S.; Cabri, W. Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold J. Med. Chem. 2014, 57, 2258-2274
45. Baruchello, R.; Simoni, D.; Grisolia, G.; Barbato, G.; Marchetti, P.; Rondanin, R.; Mangiola, S.; Giannini, G.; Brunetti, T.; Alloatti, D.; Gallo, G.; Ciacci, A.; Vesci, L.; Castorina, M.; Milazzo, F. M.; Cervoni, M. L.; Guglielmi, M. B.; Barbarino, M.; Fodera, R.; Pisano, C.; Cabri, W. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90 J. Med. Chem. 2011, 54, 8592-8604
46. Baruchello, R.; Simoni, D.; Marchetti, P.; Rondanin, R.; Mangiola, S.; Costantini, C.; Meli, M.; Giannini, G.; Vesci, L.; Corollo, V.; Brunetti, T.; Battistuzzi, G.; Tolomeo, M.; Cabri, W. 4,5,6,7-Tetrahydro-isoxazolo-[4,5- c ]-pyridines as a new class of Hsp90 inhibitors Eur. J. Med. Chem. 2014, 76, 53-60
47. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase Bioorg. Med. Chem. 2002, 10, 3555-3564
48. Kim, S. H.; Bajji, A.; Tangallapally, R.; Markovitz, B.; Trovato, R.; Shenderovich, M.; Baichwal, V.; Bartel, P.; Cimbora, D.; McKinnon, R.; Robinson, R.; Papac, D.; Wettstein, D.; Carlson, R.; Yager, K. M. Discovery of (2 S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9 H -purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor J. Med. Chem. 2012, 55, 7480-7501
49. Davies, N. G. M.; Browne, H.; Davis, B.; Drysdale, M. J.; Foloppe, N.; Geoffrey, S.; Gibbons, B.; Hart, T.; Hubbard, R.; Jensen, M. R.; Mansell, H.; Massey, A.; Matassova, N.; Moore, J. D.; Murray, J.; Pratt, R.; Ray, S.; Robertson, A.; Roughley, S. D.; Schoepfer, J.; Scriven, K.; Simmonite, H.; Stokes, S.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Brough, P. Targeting conserved water molecule: design of 4-aryl-5-cyanopyrrolo[2,3- d ]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization Bioorg. Med. Chem. 2012, 20, 6770-6789
50. Huang, K. H.; Barta, T. H.; Rice, J. W.; Smith, E. D.; Ommen, A. J.; Ma, W.; Veal, J. M.; Fadden, P.; Barabasz, A. F.; Foley, B. E.; Huges, P. F.; Hanson, G. J.; Markworth, C. J.; Silinski, M.; Partridge, J. M.; Steed, P. M.; Hall, S. E. Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90 Bioorg. Med. Chem. Lett. 2012, 22, 2550-2554
51. Miura, T.; Fukami, M. T.; Hasegawa, K.; Ono, N.; Suda, A.; Shindo, H.; Yoon, D. O.; Kim, S. J.; Na, Y. J.; Aoki, Y.; Shimma, N.; Tsukuda, T.; Shiratori, Y. Lead generation of heat shock 90 protein inhibitors by a combination of fragment-based approach, virtual screening and structure-based rug design Bioorg. Med. Chem. Lett. 2011, 21, 5778-5783
52. Suda, A.; Kawasaki, K. I.; Komiyama, S.; Isshiki, Y.; Yoon, D. O.; Kim, S. J.; Na, Y. J.; Hasegawa, K.; Fukami, T. A.; Sato, S.; Miura, T.; Ono, N.; Yamazaki, T.; Saitoh, R.; Shimma, N.; Shiratori, Y. Design and synthesis of 2-amino-6-(1 H,3 H -benzo[ de ]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors Bioorg. Med. Chem. 2014, 22, 892-905
53. Chiosis, G.; Dickey, C. A.; Johnson, J. L. A global view of Hsp90 functions Nat. Struct. Mol. Biol. 2013, 20, 1-4
54. Taldone, T.; Patel, P. D.; Patel, M.; Patel, H. J.; Evans, C. E.; Rodina, A.; Ochiana, S.; Shah, S. K.; Uddin, M.; Gewirth, D.; Chiosis, G. Experimental and structural testing module to analyze paralog-specificity and affinity in the Hsp90 inhibitors series J. Med. Chem. 2013, 56, 6803-6818
55. Patel, P. D.; Yan, P.; Seidler, P. M.; Patel, H. J.; Sun, W.; Yang, C.; Que, N. S.; Taldone, T.; Finotti, P.; Stephani, R. A.; Gewirth, D. T.; Chiosis, G. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 Nat. Chem. Biol. 2013, 9, 677-684
56. Duerfeldt, A. S.; Peterson, L. B.; Maynard, J. C.; Ng, C. L.; Eletto, D.; Ostrovsky, O.; Shinogle, H. E.; Moore, D. S.; Argon, Y.; Nicchitta, C. V.; Blagg, B. S. J. Development of a Grp94 inhibitor J. Am. Chem. Soc. 2012, 134, 9796-9804
57. Ernst, J. T.; Neubert, T.; Liu, M.; Sperry, S.; Zuccola, H.; Turnbull, A.; Fleck, B.; Kargo, W.; Woody, L.; Chiang, P.; Tran, D.; Chen, W.; Snyder, P.; Alcacio, T.; Nezami, A.; Reynolds, J.; Alvi, K.; Goulet, L.; Stamos, D. Identification of novel Hsp90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntingtons disease J. Med. Chem. 2014, 57, 3382-3400
58. Yin, Z.; Henry, E. C.; Gasiewicz, T. A. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor Biochemistry 2009, 48, 336-345
59. Tran, P. L.; Kim, S. A.; Choi, H. S.; Yoon, J. H.; Ahn, S. G. Epigallocatechin-3-gallate suppresses the expression of Hsp70 and Hsp90 and exhibits anti-tumor activity in vitro and in vivo BMC Cancer 2010, 10, 276
60. Khandelwal, A.; Hall, J. A.; Blagg, B. S. J. Synthesis and structure-activity relationship of EGCG analogues, a recently identified Hsp90 inhibitor J. Org. Chem. 2013, 78, 7859-7884
61. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of Hsp90 C-terminal nucleotide binding pocket Curr. Med. Chem. 2008, 15, 2702-2717
62. Zhao, H.; Kusuma, B. R.; Blagg, B. S. J. Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity ACS Med. Chem. Lett. 2010, 1, 311-315
63. Zhao, H.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E. L.; Brown, D.; Rajewski, R. A.; Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. J. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents J. Med. Chem. 2011, 54, 3839-3853
64. Zhao, H.; Blagg, B. S. J. Novobiocin analogues with second-generation noviose surrogates Bioorg. Med. Chem. Lett. 2013, 23, 552-557
65. Kusuma, B. R.; Khandelwal, A.; Gu, W.; Brown, D.; Liu, W.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors Bioorg. Med. Chem. 2014, 22, 1441-1449
66. Zhao, H.; Moroni, E.; Colombo, G.; Blagg, B. S. J. Identification of a new scaffold for Hsp90 C-terminal inhibition ACS Med. Chem. Lett. 2014, 5, 84-88
67. Kusuma, B. R.; Zhang, L.; Sundstorm, T.; Peterson, L. B.; Bobrowsky, R. T.; Blagg, B. S. J. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neurons glucotoxicity J. Med. Chem. 2012, 55, 5797-5812
68. Sellers, R. P.; Alexander, L. D.; Johnson, V. A.; Lin, C. C.; Savage, J.; Corral, R.; Moss, J.; Slugocki, T. S.; Singh, E. K.; Davis, M. R.; Ravula, S.; Spicer, J. E.; Oelrich, J. L.; Thornquist, A.; Pan, C. M.; McAlpine, S. R. Design and synthesis of Hsp90 inhibitors: exploring the SAR of sansalvamide A derivatives Bioorg. Med. Chem. 2010, 18, 6822-6856
69. Koay, Y. C.; McConnell, J. R.; Wang, Y.; Kim, S. J.; Buckton, L. K.; Mansour, F.; McAlpine, S. R. Chemically accessible Hsp90 inhibitor that does not induce a heat shock response ACS Med. Chem. Lett. 2014, 5, 771-776